{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Miller NJ"],"funding":["National Cancer Institute","NCI NIH HHS","Prostate Cancer Foundation"],"pagination":["131"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6258401"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(1)"],"pubmed_abstract":["<h4>Background</h4>Merkel cell carcinoma (MCC) is an aggressive skin cancer that frequently responds to anti-PD-1 therapy. MCC is associated with sun exposure and, in 80% of cases, Merkel cell polyomavirus (MCPyV). MCPyV-specific T and B cell responses provide a unique opportunity to study cancer-specific immunity throughout PD-1 blockade therapy.<h4>Methods</h4>Immune responses were assessed in patients (n = 26) with advanced MCC receiving pembrolizumab. Peripheral blood mononuclear cells (PBMC) were collected at baseline and throughout treatment. MCPyV-oncoprotein antibodies were quantified and T cells were assessed for MCPyV-specificity via tetramer staining and/or cytokine secretion. Pre-treatment tumor biopsies were analyzed for T cell receptor clonality.<h4>Results</h4>MCPyV oncoprot"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy."],"pmcid":["PMC6258401"],"funding_grant_id":["15CHAS04","R01 CA162522","P30 CA015704","UM1 CA154967","K24 CA139052"],"pubmed_authors":["Lundgren L","Miller NJ","Ramchurren N","Kulikauskas R","Cheever MA","Bhatia S","Fling SP","Church CD","Kluger HM","Nghiem P","Shinohara MM","Topalian SL"],"additional_accession":[]},"is_claimable":false,"name":"Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.","description":"<h4>Background</h4>Merkel cell carcinoma (MCC) is an aggressive skin cancer that frequently responds to anti-PD-1 therapy. MCC is associated with sun exposure and, in 80% of cases, Merkel cell polyomavirus (MCPyV). MCPyV-specific T and B cell responses provide a unique opportunity to study cancer-specific immunity throughout PD-1 blockade therapy.<h4>Methods</h4>Immune responses were assessed in patients (n = 26) with advanced MCC receiving pembrolizumab. Peripheral blood mononuclear cells (PBMC) were collected at baseline and throughout treatment. MCPyV-oncoprotein antibodies were quantified and T cells were assessed for MCPyV-specificity via tetramer staining and/or cytokine secretion. Pre-treatment tumor biopsies were analyzed for T cell receptor clonality.<h4>Results</h4>MCPyV oncoprot","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Nov","modification":"2026-07-16T11:35:12.686Z","creation":"2019-03-27T00:10:05Z"},"accession":"S-EPMC6258401","cross_references":{"pubmed":["30482247"],"doi":["10.1186/s40425-018-0450-7"]}}